Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-ALL or T-LBL
NCT05991973Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in t-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, sponsored by Zhejiang University. Started Jul 2023; status: completed.
02
Drugs
tucidinostat
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT05991973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991973.